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ABSTRACT 
The microbial community in our gastrointestinal tract, the gut microbiota, has great 
impact on our physiology. Particularly, the role for gut microbiota in host health and 
disease has been associated with modulation of gut hormones which are key players 
in the regulation of energy homeostasis. Recently, a new gut hormone, insulin-like 
peptide (INSL5) has been identified. In this thesis, we have studied the microbial 
regulation of INSL5 and its role on metabolism.  
Bariatric surgery is the most effective treatment for obesity and obesity-related 
diseases such as type 2 diabetes. There is increasing evidence that supports a role for 
gut hormones and gut microbiota in mediating the beneficial effects of bariatric 
surgery. Thus, in this thesis, we also investigated whether INSL5 and the gut 
microbiota directly contributes to the metabolic improvements following the bariatric 
procedure called vertical sleeve gastrectomy (VSG). 
In paper I, we found that Insl5 expression is higher in the colon of germ-free mice 
(mice that lack a microbiota), compared with their conventionally-raised control 
animals. We demonstrated that the elevated Insl5 expression in GF mice is a 
response to low energy levels, which could be restored by increasing the energy 
availability. In addition, we found that mice lacking INSL5 have slightly impaired 
hepatic glucose production during fasting. Thus we speculate that INSL5 might play 
a role in low energy conditions. 
In paper II, we observed that circulating fasting INSL5 levels were increased in 
human individuals following VSG. The high INSL5 levels were declined upon a 
meal test, suggesting a postprandial response. To test whether INSL5 contributes to 
the beneficial effects mediated by VSG, we performed VSG surgeries on wild-type 
and Insl5-knockout mice. The metabolic improvements in both groups of mice were 
similar after VSG. Therefore, we conclude that INSL5 is not required for the 
beneficial effects observed after VSG. 
In paper III, we characterized the longitudinal changes of the human gut microbiota 
after VSG, and we found that VSG strongly altered the microbiota composition. We 
showed that by transferring the VSG-altered gut microbiota from humans to mice, we 
also transferred the improvements in metabolic effects of VSG patients. We also 
showed that VSG surgery produced greater metabolic improvements in mice having 
a normal microbiota compared with germ-free mice. These results indicate that the 
gut microbiota is directly contributing to the beneficial effects mediated by VSG. 
In conclusion, INSL5 is a microbially regulated gut hormone which promotes 
hepatic glucose production during low energy conditions. INSL5 is also a gut 
hormone which increases after fasting following sleeve gastrectomy in humans, but it 
appears not to contribute to the beneficial effects observed after sleeve gastrectomy 
in mice. However, the gut microbiota plays an important role for the metabolic 
improvements mediated by sleeve gastrectomy. 
Keywords: gut microbiota, gut hormones, INSL5, Bariatric surgery 
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SAMMANFATTNING PÅ SVENSKA 
De bakterier som lever i vår mag-tarm kanal, tarmfloran, har stor inverkan på 
kroppens fysiologi. Tarmflorans påverkan på människans hälsa och sjukdom anses 
delvis ske genom modulering av tarmhormoner som i sin tur är viktiga aktörer inom 
reglering av kroppens energibalans. Insulin-like peptide 5 (INSL5) är ett nyligen 
identifierat tarmhormon. I den här doktorsavhandlingen har vi studerat hur tarmfloran 
reglerar nivåerna av INSL5 och dess roll inom metabolism. 
Bariatrisk kirurgi (viktminskning kirurgi) är den effektivaste behandlingen mot fetma 
och fetma relaterade sjukdomar såsom typ 2 diabetes. Mer och mer forskning tyder 
på att tarmhormoner och tarmfloran är delaktiga i de hälsobringande effekterna av 
bariatrisk kirurgi. Därmed, har vi i den här doktorsavhandlingen också studerat ifall 
INSL5 och tarmfloran bidrar direkt till de hälsoförbättringarna som sker efter det 
bariatriska ingreppet vertical sleeve gastrectomy (VSG).  
I delarbete I, upptäckte vi att gennivåerna av Insl5 är högre i tjocktarmen i bakterie 
fria möss jämfört med kontroll mössen som har en normal bakterieflora. Vi visade att 
de förhöjda gennivåerna av Insl5 i bakterie fria möss var en reaktion på låga 
energinivåer, som kunde återställas genom att öka energi tillgången i mössen. 
Dessutom upptäckte vi att möss som saknar INSL5 har något försämrad 
glukosproduktion från levern under fastetillstånd. Därför spekulerar vi att INSL5 
möjligen har en roll i tillstånd med låg energi.  
I delarbete II, observerade vi att serumnivåer av INSL5 efter fasta var förhöjda i 
människor som genomgått VSG. De höga INSL5 nivåerna sjönk efter intagandet av 
en standardiserad måltid. Vi testade ifall INSL5 bidrar till de hälsoförbättringar som 
orsakas av VSG genom att utföra VSG operationer på möss som saknar INSL5 och 
vanliga kontroll möss. VSG gav samma metabola förbättringar i båda mössen. Därför 
är vår slutsats att INSL5 inte krävs för att bidra till de hälsoförbättringar som sker 
efter VSG. 
I delarbete III, studerade vi hur människors tarmflora förändrades med tiden efter 
VSG, och vi upptäckte att VSG kraftigt förändrade den bakteriella sammansättningen 
i tarmen. Vi visade att genom att överföra den VSG-förändrade tarmfloran från 
människor till möss så kunde vi också överföra de metabola förbättringarna från 
patienterna som genomgått VSG. Vi visade också att VSG operationer orsakade 
tydligare hälsoförbättringar på möss som har en normal bakterieflora jämfört med 
bakterie fria möss. Dessa resultat indikerar att tarmfloran har en direkt bidragande 
roll i de hälsobringande effekterna av VSG. 
Vår slutsats är att INSL5 är ett tarmhormon som regleras av tarmfloran, och den 
stimulerar glukosproduktion från levern under låga energi förhållanden. INSL5 är 
också ett tarmhormon vars nivåer ökar efter VSG i människor, men den bidrar inte 
direkt till de hälsobringade effekterna som sker efter VSG i möss. Däremot spelar 
tarmfloran en betydande roll för de metabola förändringarna som sker efter VSG. 
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1 INTRODUCTION 
1.1 Gut microbiota 
Our human body is home to roughly 100 trillion microbes, the majority 
of these microbes inhabit our gastrointestinal tract, called gut 
microbiota (1). We have evolutionary coevolved into a symbiotic 
relationship with the gut microbiota; we provide them with a nutrient-
rich environment which sustains their continuous growth, while they 
perform several metabolic and biochemical functions like digest 
nutrients otherwise indigestible by ourselves, and provides protection 
against invading pathogens (2, 3). The gut microbiota composition in 
mammalians is clearly different from environmental communities 
residing in soils, sea-water, lakes and etc. (4).  
The gut microbiota is composed by bacteria, archaea, yeasts, viruses 
and fungi (5, 6). However, the surge in gut microbiota research in the 
last decade has been focused on the bacterial species, although recently 
interest is growing on the non-bacterial components (7). But in the 
light of this thesis which focuses is on the bacterial population of the 
microbial community, will for simplicity´s sake be referred as the “gut 
microbiota”. The microbiota populating our body is composed of at 
least as many bacteria as human cells (8). On earth, 100 different 
bacterial phyla have been detected, but only seven are found 
consistently in our gut; Firmicutes, Bacteroidetes, Actinobacteria, 
Proteobacteria, Verrucomicrobia, Tenericutes, and Fusobacteria. Out 
of these, Firmicutes and Bacteroidetes represent together up to 90% of 
the bacterial population, while the remaining phyla make up the last 
10% (9, 10). More than 1000 different species belonging to the 
previously mentioned phyla have been identified in healthy individuals 
(9). Although the composition of the microbiota varies tremendously 
between individuals, a common conserved “core” microbiota can be 
found in large cohorts of the human population (10).  
We are colonized throughout our gastrointestinal tract, but the species 
and abundance residing in each section varies along the intestinal tract, 
this is partly due to nutrient availability, pH and oxygen gradient 
ranging from the stomach to the colon (11, 12), creating distinct 
environments which make different species thrive according to their 
preferred milieu. In humans, the bacterial density increases from the 
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upper to the lower part of the gastrointestinal tract, starting with the 
proximal intestine (duodenum) colonized by 103 bacteria/ml consisting 
of Lactobacillus and Streptococcus, continuing with the most distal 
part of the small intestine (ileum) with 106-108 bacteria/ml and 
consisting of Enterobacteria, Enterococcus, Bacteroides, Clostridium, 
Lactobacillus and Veilonella. Finally in the large intestine (colon), we 
end up with 1011 bacteria/ g content, with genera belonging to 
Bacteroides, Eubacterium, Bifidobacterium, Ruminococcus, 
Peptostreptococcus, Propionbacterium, Clostridium, Lactobacillus, 
Escherichia and Streptococcus (13, 14). 
More importantly, the impact of gut microbiota on host physiology 
extends beyond the intestine. Either directly through microbial 
produced metabolites, such as bile acids and short chain fatty acids 
(SCFAs) (15), which are taken up from the intestinal lumen into our 
bloodstream, and act as signaling molecules on our cells (16), or 
indirectly by affecting the intestinal cells, which are in close proximity 
to the microbes, and alter their secretion of for example inflammation 
markers or hormones which in turn also leads to significant 
consequences for the whole body (17). Increasing evidence also 
suggest that the gut microbiota has an important impact on the gut-
brain cross-talk, by not only local interaction with the enteric nervous 
system, but also with direct communication with the central nervous 
system (18). Moreover, various diseases have been associated with 
disturbances in the microbial composition (19), making it clear that the 
gut microbiota is both beneficial and potentially harmful for us. Since 
the gut microbiota can be manipulated through external factors such as 
diet (20-22), probiotics (23, 24), and antibiotics (25), studying the gut 
microbiota is a very interesting research topic for understanding and 
treating human diseases (26). 
1.1.1 Studying the gut microbiota- a historical review 
The study of gut microbiota is a rapidly growing research field that has 
received increasing attention the last decade-one might think that this 
is a relatively young research topic. However, already in 1885, the idea 
of using germ-free (GF) animals (animals that are completely sterile 
and free of microorganisms) and gnotobiotic animals (animals 
colonized with only one or several known strains of microorganisms) 
in nutritional studies was raised by Louise Pasteur. He made the 
following statement (27). 
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For several years during discussions with young scientists in my 
laboratory, I have spoken of an interest in feeding a young animal 
(rabbit, guinea pig, dog or chicken) from birth with pure nutritive 
products which have been artificially and totally deprived of the 
common microorganisms. Without affirming anything, I do not conceal 
the fact that if I had time, I would undertake such a study, with the 
preconceived idea that under these conditions life would have become 
impossible. If this work could be developed simply, one could then 
consider the study of digestion by the systematic addition to the pure 
food, of one or another single microorganisms or diverse 
microorganisms with well-defined relationships. 
There are clearly several difficulties that will need to be overcome 
when rearing GF animals. But two main problems are: how and with 
what to feed the animal, and how to keep the GF animal isolated from 
its contaminating surroundings. Within 10 years after Pasteur´s first 
statement, Nuttal and Thierfelder delivered guinea pigs into a germ-
free environment by caesarian section in 1895 (28). The guinea pigs 
survived for 13 days on a diet of diluted sterilized cow´s milk. The 
animals were examined post mortally and they showed enlarged 
caecums. Others followed Pasteur´s original concept. In 1898, 
Schottelius obtained the first GF chicken (29); however infection 
occurred in all their experiments. By 1912, Küster was able to rear two 
GF goats (30), which were fed with sterilized milk from the mother, to 
the age of 12 and 35 days respectively, before they became infected. 
Although the GF goats grew at the same rate as control goats reared on 
sterilized milk in a normal environment, Küster concluded that the 
importance of gut microbiota for the host cannot be determined until 
after the animals have been weaned.  
In 1932, at the University of Lund, Sweden, Glimstedt resumed the 
study of GF guinea pigs in order to study the morphology and 
histology of lymphoid tissue (31). He made an effort on understanding 
the value of nutrition in rearing GF animals. They were fed sterilized 
milk together with solid food and vitamins which were sterile filtered, 
which resulted in the fact that GF guinea pigs now often survived up to 
2 months. GF and control animals (animals reared in normal bacteria 
containing surroundings) fed on the same diet did not differ in 
viability, and growth was only slightly lower in GF animals compared 
with control animals. The GF animals showed greater appetite than the 
control animals, and they displayed large caecums and the consistency 
of their faeces was softer with higher water content. The GF animals 
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also exhibited immature lymphoid organs compared with the control 
animals.   
During the 1940s, Reyniers and his co-workers at the Lobound 
Laboratory, University of Note Dame, US, attempted to rear higher 
organisms in GF conditions; they experimented with monkeys, dog, 
cats, rats, mice, guinea pigs and rabbits (32-34). He described the GF 
rearing system as a very complex program which requires a great deal 
of experience to design, construct and operate. It was also expensive. 
To run the system efficiently it required numerous specialized staff 
such as feeders, sterilization crews, maintenance machinist, 
bacteriologists, biochemists and pathologists etc. with their helpers and 
technicians (35-37) . The newborn pups were fed once every hour for 
the first 4 weeks of life which required 3 technicians to work by shifts. 
Reyniers used sufficient diet mixtures together with large amounts of 
pure vitamins and crude yeast and liver extract which resulted in good 
growth of the GF animals compared with the diet mixture alone (38). 
Reyniers and his colleagues succeeded to rear GF rats for a period of 5 
months, and within this time, the GF rats gave birth to several litters 
which made Reyniers´ group the first one to successfully obtain a 
second generation of mammals in a GF environment, which 
circumvented the requirement for handfeeding the pups. They also 
succeeded in rearing GF guinea pigs for 8 months but their growth was 
poor, and most of the animals died of starvation after 2 months. 
Reyniers´ results point to the fact that the diet is of importance in 
rearing animals in an environment absent of microorganisms. As a 
matter of fact, a review of the literature from this period clearly shows 
that investigators who have taken care to supply large amounts of 
vitamins have been most successful (39).   
During the same period, Gustafsson and his colleagues reestablished 
the GF work at Lund University. In 1948, he successfully reared GF 
rats (39), and by 1956 they achieved rearing of rats for consecutive 
generations (40).  
In the 1950s, scientists had finally gained sufficient knowledge about 
nutritional requirements to establish and keep GF mice and rat colonies 
for generations to come. Altogether, it took 50 years to complete the 
germ-free experiment. 
Ying Shiuan Lee 
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1.1.2 Gut microbiota and effects on host physiology 
The gut microbiota is capable of many processes that are essential for 
several aspects of host biology. For example, they enable us to digest 
food particles that are otherwise indigestible and they produce vitamins 
(41), together with other physiological processes such as development 
and differentiation of the intestinal epithelium and immune system (42-
44). They have also shown to be required for protection against 
invasion of pathogenic bacteria (3), development and maintenance of 
epithelial integrity and homeostasis (45), bone mass regulation (46), 
and host behavior (47, 48). In particular, the effect of gut microbiota 
on host metabolism (49, 50) has been the topic of intense research the 
last decade, for the purpose of this thesis, which will be discussed in 
more detail.  
1.1.3 Gut microbiota and energy metabolism 
Evolutionary, food has been scarce which have programmed animals 
to protect energy stores by promoting fat storage. Nowadays, diets 
have changed and energy-rich foods have become easily accessible; 
making obesity rather than undernutrition a concern for human health 
in many developed countries. Although, other factors than type of 
calorie and availability seem to be important. Recent studies performed 
during the past decade provide evidence which suggests that the gut 
microbiota might play a role in energy harvest, storage and 
expenditure.  
Gut microbiota promotes energy harvest and storage  
Since the 1950s, a number of animal species have been reared as GF, 
which have allowed scientists to investigate the role of microbiota in 
metabolism (51, 52). Two studies, using GF mice, conducted 10 years 
ago strongly supported the role of gut microbiota in obesity (49, 53). 
They showed that GF mice gain less weight compared with their 
conventionally-raised (CONV-R) control animals, despite that they ate 
more, because gut microbiota influenced energy harvest and storage 
and energy expenditure (49, 53). The microbiota increased energy 
storage by promoting de novo lipogenesis in the liver, and deposition 
of triglycerides into adipose tissue by suppressing the expression of 
angiopoietin-like protein 4 (a lipoprotein lipase inhibitor) (49). 
Furthermore, they demonstrated that introducing microbiota from 
CONV-R mice into GF mice resulted in increased body fat and insulin 
resistance within two weeks.   
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Altered gut microbiota in obesity  
There is also evidence showing that the gut microbiota residing in 
obese and lean individuals is different. A transfer of the intestinal 
content from obese mice (ob/ob) into GF mice resulted in greater 
increase of total body fat compared with the GF mice colonized with 
microbiota from lean donors (54). The ‘obese microbiota’ is suggested 
to have an increased capacity to harvest energy from the diet. The 
same researchers also demonstrated that both in mice and humans, 
obesity is associated with changes in the gut microbiota composition 
(55, 56). 
Recent studies have identified that diet, especially fat, is a strong 
modulator of the microbiota (50, 57). For this reason, there is 
increasing evidence that the high fat intake rather than the obesity per 
se has a direct effect on the microbiota (58, 59). A later study, on 
discordant twins for obesity, where one twin is obese and the other is 
lean, showed that the phenotype can be transferred with the gut 
microbiota, where the change in total body fat is significantly greater 
in the mice that received fecal microbiota from the obese twin (60). In 
addition, several clinical studies have suggested a role of the gut 
microbiota in obesity (61). However, a causal relationship between 
microbiota and obesity in humans remains to be demonstrated. 
Although, recent studies have established the microbiota as a 
contributing factor for obesity, we should consider that the major 
factor driving obesity is the diet through excess energy intake. Diet is 
also the primary factor that determines the microbiota composition, 
where studies in both animals and humans reveal that dietary changes 
rapidly alter the microbiota composition (21, 22). Increasing the 
understanding of the interactions between diet and microbiota will 
provide new strategies to potentially treat and/or prevent obesity in the 
future. 
1.2 Fasting and feeding 
Glucose is one of the main fuels for all animals. It is metabolized by 
our cells to produce adenosine triphosphate which is used as energy to 
power millions of biochemical processes that take place in the body 
(62). We obtain glucose from the food we eat, which is absorbed in the 
small intestine and travels to the liver through the hepatic portal vein. 
In the liver, glucose is converted and stored as glycogen, which can be 
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reconverted to glucose and released into the circulation when blood 
glucose levels are low (63). All cells in the body requires energy, and 
most can use other fuels such as lipids (64). However, neurons are 
almost exclusively dependent on glucose for their energy supply (65). 
Therefore, it is important for the body to maintain constant blood 
glucose levels for the nervous system to function properly.  
During the day, blood glucose levels fluctuate according to the 
variation in food intake. After a meal, called post-absorptive or 
postprandial state, the blood glucose rise, and most of it is taken up by 
the cells in the body to make energy and the excess is converted and 
stored as glycogen by the liver (66, 67), which make the blood glucose 
level decrease. 
Several hours after a meal, blood glucose level begins to drop, and the 
body enters an early-fasting state. Glycogen stored in the liver is now 
broken down into glucose (glycogenolysis) and released into the 
bloodstream (68). The liver also performs gluconeogenesis, which is 
endogenous production of glucose using substrates such as lactate, 
alanine, glycerol or amino acids (68-70). Together, these two processes 
in the liver maintain blood glucose level also during prolonged fasting.  
After several days of starvation, the cells in the body shift from 
glucose to fatty acid utilization for fuel (64, 71-73). Free fatty acids are 
released from adipose tissue through lipolysis (74, 75). The liver 
utilizes free fatty acids to generate energy, resulting in increased 
acetyl-CoA formation, which is converted to ketone bodies 
(acetoacetate, D-β-hydroxybutyrate, and acetone), and released into the 
blood (76). Ketone bodies can be used as energy by the brain during 
times of starvation, which can provide a third of the energy 
requirements (77). The heart also uses ketone bodies as fuel during 
starvation (78). 
The body needs to maintain the blood glucose level within a relatively 
narrow range, despite these daily fluctuations, and the mechanisms that 
maintain it within these limits are greatly controlled by two important 
hormones-insulin and glucagon. Insulin signals the fed state, whereas 
glucagon signals the fasting state (62). These two hormones and their 
role in glucose metabolism will be discussed in more detail in the next 
section. 
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1.2.1 The effects of fasting and feeding on circulating 
hormones 
Hormones are signaling molecules produced by glands or cells that are 
released into the circulation to affect whole body physiology and 
behavior. Hormones enable communication between organs and 
tissues to regulate many physiological activities such as digestion, 
metabolism, stress, growth and reproduction (79-82). For the purpose 
of this thesis, the focus will be on the hormones involved in glucose 
metabolism, and how they regulate fuel utilization during fasting and 
feeding. The key regulatory hormones of glucose metabolism are 
insulin and glucagon. 
Insulin 
After a meal, the concentration of glucose and amino acids rises in the 
blood, which leads to the secretion of insulin from the β-cells of the 
pancreas (83-85). The most potent stimulus of insulin is blood glucose, 
but there are other factors that can stimulate insulin secretion. These 
stimuli include increased plasma levels of amino acids (86), hormones 
released from the gut following a meal (e.g. incretins such as GIP and 
GLP-1) (87); and parasympathetic stimulation via the vagus nerve (88, 
89). Insulin has three ways to lower the blood glucose after meal 
ingestion: 1) it signals to the peripheral tissue, primarily muscle and 
adipose tissue to increase their glucose uptake (90); 2) accelerates the 
conversion of glucose to glycogen in the liver, to promote glycogen 
storage (91, 92); and 3) inhibits glucagon secretion from pancreatic α-
cells, which signals to the liver to stop producing glucose through 
glycogenolysis and gluconeogenesis (93-95). Insulin also acts to 
stimulate fatty acid synthesis, triglyceride storage in the adipose tissue 
and protein synthesis in the liver and muscle tissue (90, 96). In 
essence, insulin provides an anabolic signal. 
 
Glucagon 
In contrast, the blood glucose level decrease below the normal range 
during fasting, which stimulates the release of glucagon from the α-
cells in the pancreas (97). Glucagon is the major hormone stimulating 
hepatic glucose production which maintains the blood glucose level at 
a normal range during fasting. Glucose is produced by the liver via two 
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processes: glycogenolysis and gluconeogenesis. During the first hours 
of fasting, glucose is made available primarily through glycogenolysis. 
Over longer period of fasting, when the glycogen stores are depleted, 
glucose is produced by gluconeogenesis (98). The liver is the major 
organ performing endogenous glucose production; however at extreme 
starvation the kidney also significantly contributes to glucose 
production to maintain systemic blood glucose (99, 100). Both organs 
contain Phosphoenolpyruvate carboxykinase (PEPCK) and Glucose 6-
phosphatase (G6Pase), two key enzymes involved in gluconeogenesis 
(101, 102). They are partially controlled by glucagon and markedly 
upregulated by fasting (103-106). In essence, glucagon provides a 
catabolic signal. 
 
The regulation of glucose homeostasis is however not mediated by 
only two hormones; in fact it is a multi-hormonal system. Other 
hormones that can influence blood glucose level are: epinephrine, 
cortisol, somatostatin and growth hormone which are all blood glucose 
raising hormones (107).  
 
1.2.2 Fasting and gut microbiota 
The gut microbiota has been shown to provide beneficial effects during 
fasting periods.  In 1968, Tennant et al. observed that mice containing 
microbiota survived significantly longer than GF mice when starved. 
Although body weight loss between the groups was similar, the GF 
animals died sooner (108). The difference in survival rate might 
instead be explained by alterations in the metabolic processes in GF 
animals, and that they have lower flexibility to switch between fuels. A 
more recent study revealed that the gut microbiota regulates ketone 
body metabolism during fasting. Fasted GF mice had reduced hepatic 
ketogenesis, which lead to unfavorable metabolic changes in the heart 
tissue (109), and may also indicate that they are less efficient in 
adapting to fasting.  
However, fasting and energy deprivation shapes the gut microbial 
community which can affect host metabolism (110-112). A recent 
study reported that life-long calorie restriction in mice significantly 
changes the gut microbiota profile, consisting of an enrichment of 
bacteria species positively correlated with lifespan, and depletion of 
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species negatively correlated with lifespan (111). In addition, another 
study showed that the impaired growth phenotype of undernourished 
children could be transmitted by the microbiota to recipient animals 
(110). The gut microbiota also directly affects the local energy status 
in the gut. Microbes produce butyrate- a short chain fatty acid (SCFA), 
by fiber fermentation, which is used as fuel for the epithelial cells 
lining the colon (colonocytes) (113, 114).  Thus the microbiota is 
affected by both nutrient composition and amount.  
1.3 The gastrointestinal tract 
The gastrointestinal (GI) system is the gateway for food to enter our 
body. Rather than being a passive player, it sends effective signals to 
influence feeding behavior and contributes to the maintenance of 
energy balance. It is responsible for the first interaction between the 
food we eat and our body, through digestion and absorption of the 
ingested nutrients (115). Simultaneously, functioning as a highly 
specialized sensory organ, composed of specialized cells called 
enteroendocrine cells, which are located throughout the GI tract. 
Enteroendocrine cells are able to sense and respond to specific 
nutrients, by releasing gut hormones, which control energy balance by 
their actions on peripheral target organs (116, 117). Signals from the 
gut hormones are important regulators of food intake, gut motility and 
glucose homeostasis. Gut hormones regulate glucose homeostasis by 
enhancing insulin secretion following food ingestion, and is thus called 
incretin hormones (79). Glucagon-like peptide (GLP-1) 1 is the most 
well studied incretin that in  addition to maintain glucose homeostasis 
also suppress appetite (118). 
 
More recently, there is a growing concept that the gut microbiota is 
also serving as an endocrine organ (16). The gut microbiota has 
metabolic capacity to produce and regulate multiple metabolites that 
reach the circulation and influence systems that are well beyond the GI 
tract (50, 119-121). One such class of metabolites is bile acids that can 
signal through either nuclear receptors such as FXR or G-protein 
coupled receptors such as TGR5, which influences whole body 
metabolism (122, 123). Thus, with this ability to impact the functions 
of distal organs and systems, in many aspects, the gut microbiota 
resembles an endocrine organ.  
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1.3.1 Gut hormones 
Gut hormones are released by specialized epithelial cells called 
enteroendocrine cells which are distributed among other cell types in 
the GI tract. Enteroendocrine cells represent less than 1% of the total 
gut epithelial cell population, but the GI tract is still the largest 
endocrine organ in the body, as it produces over 20 hormones. Gut 
hormones are expressed by different genes and produced by a variety 
of enteroendocrine cells. Gut hormones produced by the 
enteroendocrine cells include: gastrin (G cells), ghrelin (A/X cells), 
cholecystokinin (CCK); (I cells), serotonin (enterochromaffin cells), 
glucose-dependent insulinotropic peptide (GIP) (K cells), GLP-1 and 
peptide YY (PYY) (L cells) (124-127). The peptides are accumulated 
in secretory granules and secreted upon stimulation, where they can act 
locally or on distant organs through the bloodstream (128-130). Food 
ingestion, digestion and absorption of nutrients such as fatty acids, 
amino acid, lipids and carbohydrate, regulate gut hormone release 
(131). Upon release, the gut hormones act locally, peripherally and 
centrally to regulate energy balance, including appetite, glucose 
metabolism and digestion (79, 118). Several hormones involved in 
regulation of energy homeostasis and their functions are listed in Table 
1.  
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Table 1. Gastrointestinal hormones involved in food intake and/or 
glucose homeostasis 
Gut hormone Site of 
release 
Organ  Function 
Cholecystokinin I-cells Upper 
small 
intestine 
 
 
 
 
• Stimulates gall bladder 
contraction 
• Stimulates bile and pancreatic 
secretions 
• Influences gut motility 
• Increases satiety 
Gastrin G-cells Stomach 
and 
Duodenum 
 
• Stimulates gastric acid production 
Ghrelin 
 
X/A-like 
cells 
Stomach 
 
 
• Increases appetite 
 
Glucagon like 
peptide-1 
L-cells Distal small 
intestine 
and colon 
 
 
 
• Stimulates insulin release 
• Inhibits gastric acid release and 
gastric emptying 
• Increases β-cell mass 
• Increases satiety 
Glucose-
dependent 
insulinotropic 
polypeptide 
K-cells Duodenum 
and 
jejunum 
 
 
• Stimulates insulin secretion 
• Influences fatty acid metabolism 
• Increases β-cell proliferation 
Peptide YY L-cells Distal small 
intestine 
and colon 
• Inhibits gastric motility 
• Increases satiety 
 
1.3.2 Gut hormones during fasting and after feeding 
The gut secretes hormonal products which communicate with the brain 
to regulate appetite and energy expenditure. These endocrine signals 
are conveyed by vagal afferent nerves innervating the GI tract (132). 
Vagal afferent fibers respond to a large number of gut hormones (133), 
and mediate their actions through communication with the brainstem 
and hypothalamic areas. The gastrointestinal vagal fibers terminate 
mostly in the nucleus tractus solitaris (NTS) of the brainstem, thus 
establishing a direct communication between the enteroendocrine cells, 
through secreted hormones, with the central nervous system (134). 
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However, it is also possible for hormones to enter the circulation and 
pass through a certain part of the brain which has a leakier blood-brain 
barrier, to target the CNS directly (135).  
During fasting, ghrelin is released from the stomach, which increases 
our appetite for food intake (136). During and after eating, the levels of 
hormones that promote appetite decrease. Instead there is an increase 
of hormones released from the enteroendodocrine cells in the 
duodenum and jejunum in response to food ingestion. These hormones 
include CCK, which increases satiety and stimulate gall bladder 
contraction and pancreatic enzyme release (137-139), as well as GIP 
which enhances insulin secretion (140, 141). Other hormones such as 
GLP-1 and PYY are released from more distal regions of the intestine, 
which actions stimulates insulin secretion and satiety, together with 
slowing gut motility (142-146).  
1.3.3 Gut hormones and metabolic disorder 
The role of gut hormones in obesity has been studied immensely. 
Some important gut hormones and their role in obesity will be briefly 
discussed in this section.  
Ghrelin 
Many studies conducted in healthy volunteers have confirmed that 
ghrelin treatment increases food intake (147). Furthermore, circulating 
ghrelin has been shown to be negatively correlated with BMI (148). 
Ghrelin is suggested to have a long term effect on the role of regulating 
body weight, since obese individuals displayed an altered ghrelin 
profile in response to fasting and eating. They do not demonstrate a 
peak of ghrelin after fasting and the level does not rapidly fall in food 
response (149-151). However, mice lacking ghrelin signaling appear to 
have normal body weight and normal food intake (152, 153), although 
mice treated with ghrelin demonstrated increased food intake (154). 
PYY 
Obese individuals have demonstrated lower fasting PYY levels (155), 
as well as a blunted PYY response after food intake (156). In addition, 
studies in mice showed that circulating PYY levels decreased in mice 
fed a high-fat diet (157). The Pyy knockout mice generated by 
Batterham and colleagues displayed increased food intake and fat 
tissue, which could be reversed by exogenous PYY treatment (157, 
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158). In line with this, one clinical study showed body weight 
reduction in obese individuals, with PYY administration (159). Also, 
increased postprandial PYY response has been reported to play a role 
in the beneficial effects following bariatric surgery (160, 161).  
GLP-1 
The development of GLP-1 receptor agonists has offered new ways to 
treat type 2 diabetes, which effectively reduce blood glucose levels and 
body weight while having low risk of hypoglycemia (162). In humans, 
GLP-1 has shown a dose dependent reduction of food intake in both 
obese and lean individuals (163). There are many studies providing 
evidence to support the role of GLP-1 in obesity, although several 
studies have shown that there is no difference in fasting GLP-1 level 
between obese and lean humans (164). Nonetheless, weight loss in 
obese adults and children is associated with reduced fasting GLP-1 
(165, 166). GLP-1 secretion after food intake is considerably 
attenuated in obese individuals compared to lean controls (167, 168), 
however some studies showed a different post-prandial response (169). 
Furthermore, several studies have reported an increase in postprandial 
circulating levels of GLP-1 after bariatric surgery (170). The potential 
role of GLP-1 on the metabolic effects following bariatric surgery will 
be discussed in more detail later.  In addition, studies on rodents 
demonstrated that the administration of GLP-1 significantly reduces 
the food intake (171). However, mice with complete disruption of 
GLP-1 receptor signaling eat normally and do not become obese with 
aging or after high-fat intake (172, 173). Similarly, as described above, 
the same phenomenon was observed for ghrelin. A mouse model 
lacking a specific hormone does not display any phenotype, while a 
pharmacological treatment with the same hormone results in an 
observable effect. 
1.3.4 Insulin-like peptide 5 
Insulin-like peptide 5 (INSL5) was first identified 1999 by screening 
the expressed sequence tags (EST) databases (174). Human and 
murine INSL5 are both polypeptides of 135 amino acids, with the 
classical protein structure of the insulin/relaxin superfamily, consisting 
of an A and B-chain connected with disulfide cross-links (175). A 
series of studies have detected the highest INSL5 expression in colonic 
tissue (174), more specifically in enteroendocrine cells (176-178), and 
some have also revealed the presence of INSL5 in a variety of human 
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tissues, including the brain (179). INSL5 has been reported to bind to 
the G protein coupled relaxin/insulin-like family peptide receptor-4 
(Rxfp4) (179-181).  
While, some members of the relaxin family have important roles in 
reproductive physiology and tissue remodeling, the function of INSL5 
remains uncertain (182). However, a recent study showed that INSL5 
is a hormone secreted by L-cells in the colon, which enhances food 
intake in mice (178). In agreement with being an appetite increasing 
hormone, circulating INSL5 was increased by fasting and calorie 
restriction, and declined with feeding. Another study reported a role of 
INSL5 in regulation of glucose homeostasis, where they observed 
reduced insulin secretion and β-cell mass in Insl5-/- mice (183). In 
addition, INSL5 has been shown to enhance glucose-stimulated insulin 
secretion both in vivo and in vitro, suggesting an incretin role of INSL5 
(184). 
1.3.5 Gut hormones and gut microbiota 
As mentioned earlier, the gut microbiota is capable of producing 
metabolically active metabolites which functions much like hormones 
in our body (16). However, accumulating evidence shows that the gut 
microbiota can also influence host metabolism through their impact on 
gut hormones (16, 185, 186). Modulating the gut microbes with 
indigestible dietary fiber treatments has been associated with changes 
in gut hormone levels. Cani and colleagues have shown a connection 
between gut microbes and GLP-1 levels in several studies (187). In 
rats, oligofructose feeding (which shifted the bacterial composition) 
resulted in greater number of GLP-1 producing enteroendocrine cells 
in the colon. Obese mice treated with prebiotic carbohydrates had 
altered gut microbiota and increased levels of GLP-1 and GLP-2 (188).  
The pathway of which the microbiota influences the gut hormone 
secretion is believed to be mediated through SCFAs actions on their 
receptors GPR41 and GPR43, which are expressed by the 
enteroendocrine cells (189, 190). SCFAs are produced by bacterial 
fermentation of carbohydrates from the diet. Thus, SCFAs (e.g., 
butyrate, propionate, acetate) function as an energy source as well as a 
signaling molecule, and their abundance is directly related to the 
bacterial species composition in the gut (191-193). A recent study 
performed by Wichmann et al., showed that GF mice had increased 
circulating GLP-1 and GLP-1 producing enteroendocrine cells in the 
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GI tract, which was associated with slower gut transit (194). 
Furthermore, the gut microbiota may also stimulate GLP-1 secretion 
through modulation of bile acids which activate TGR5 receptors 
located on L-cells (195).  
1.4 Bariatric surgery 
Over the past decade, obesity has become a major health concern all 
around the world (196, 197). Obesity has now reached pandemic levels 
in the United States, as well as other countries (198). In the United 
States, two thirds of the population meets the criteria for overweight, 
and over one third of the population is obese (199). There is growing 
evidence that support bariatric surgery as the most effective treatment 
option for severe obesity and its related diseases (200). As a result, the 
number of bariatric procedures has increased significantly during the 
past few decades (201, 202).  
Bariatric surgery has been proven to be much more effective in treating 
obesity than the traditional non-surgical treatments such as diet and 
exercise (200). In contrast, dieting has been associated with only a 
modest long-term weight loss for most patients (203-206). In a study, 
less than 20% of the individuals succeeded to achieve and maintain a 
weight loss of 10% over 1 year (206). In contrast, bariatric surgery 
produces weight loss that ranges between 50% - 75% of excess body 
weight (207), which is maintained longer than can be achieved by 
changes in lifestyle (208). Some studies indicate that the weight loss 
can be sustained for up to 16 years after surgery (209), whereas 
lifestyle and pharmacological interventions often results in weight 
regain after 6 to 24 months (203, 210). Therefore, bariatric surgery is 
currently considered the most effective treatment against obesity. 
1.4.1 Bariatric surgery types 
Bariatric surgery is suggested to promote decreased energy intake in 
two ways, that is by restriction and malabsorption (211). The 
restriction method limits the amount of food to be consumed. 
Procedures such as adjustable gastric banding (AGB) and vertical 
sleeve gastrectomy (VSG) are examples of the restriction type of 
surgery. In combination with food restriction, energy intake can be 
limited by bypassing segments of the small intestine, which results in 
caloric malabsorption, an example of this type is Roux-en-Y gastric 
bypass (RYGB) (211). A global overview of bariatric surgery in 2013, 
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revealed that the most commonly performed procedure in the world 
was RYGB, 45%; followed by VSG, 37%; and AGB, 10% (212). In 
addition, VSG is currently the most popular procedure in the 
USA/Canada and in the Asia/Pacific regions, whereas RYGB is more 
frequently performed in Europe and Latin/South America. While, 
vertical banded gastroplasty (VBG) was the predominant procedure 
during the 1980s, it has now rapidly fallen in popularity due to 
insufficient long-term maintenance of weight loss, and long-term 
complications (213). A short description of some procedures follows 
below. 
Vertical banded gastroplasty (VBG) 
A partitioning of the stomach is created with staples and a rubber band, 
resulting in the formation of a small pouch in the upper part of the 
stomach. The passage of the food is restricted by the small pouch 
before reaching the stomach (213).  
Adjustable gastric banding (AGB) 
A synthetic adjustable gastric band is placed below where the 
esophagus is attached to the stomach, creating a stomach pouch. 
However, the stomach remains intact. The band can be inflated and 
deflated to adjust the degree of constriction around the stomach, in 
order to limit the amount of food the patient can eat, as well as 
maintaining satiety by slowing gastric emptying (211).  
Vertical sleeve gastrectomy (VSG) 
In the VSG procedure, 80% of the greater curvature of the stomach is 
removed, creating a tight funnel for the food to pass through the 
esophagus to the duodenum (211).  
Roux-en-Y gastric bypass (RYGB) 
RYGB procedure consists of a restrictive and a malabsorptive 
component. It involves creating a small stomach pouch which is 
connected to a limb of distal intestine (jejunum), bypassing the 
proximal intestine (duodenum). This procedure results in bypassing the 
potential absorption of nutrients in the duodenum and proximal 
jejunum. It also reduces the time in which bile and pancreatic enzymes 
can mix with the food (211).  
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A recent meta-analysis comparing studies of RYGB, VSG and AGB 
demonstrated similar weight loss of approximately 60% of excess body 
weight, was produced after RYGB and VSG, that was superior to the 
weight loss induced by AGB (214). AGB also had the highest number 
of complaints from patients (20%) who failed to achieve sufficient 
weight loss. In addition, resolution rate of comorbidities after surgery, 
such as type-2 diabetes, was lowest in AGB (207).  However, AGB 
seems to be a safer procedure, with frequent but less severe 
complications (214). The more recent VSG procedure achieves similar 
reduction in HbA1c and also rates (24% of patients) of type 2 diabetes 
resolution have been reported for RYGB (38% of patients) after 3 
years (215).  
1.4.2 Bariatric surgery and metabolic improvements 
beyond weight loss 
A significant cause of death in obese patients is cardiovascular disease 
(216). Obese patients have dyslipidemia, a plasma lipid profile which 
is associated with increased risk of cardiovascular disease (217). 
Bariatric surgery has other powerful effects than only to reduce body 
weight; it also produces improvements on other metabolic parameters 
such as glucose tolerance and plasma lipids. One study reported that at 
least 70% of the patients, which have been subjected to different types 
of bariatric procedures, displayed an improved plasma lipid profile 
post-surgery (207). Specially, improvements have been reported in 
humans after RYGB (218), AGB (219) and VSG (220). However, 
RYGB has been uniquely reported to lower the total cholesterol in 
comparison to the other two surgery types (221, 222). Since RYGB 
appear to induce weight loss superior to AGB, but comparable to VSG, 
the key question is whether the improved lipid profile occur 
independent of weight loss. 
Diabetes is also a comorbidity frequently related to obesity (223). 
Typically, patients with abnormal glucose tolerance have higher 
insulin levels after glucose administration, which is a compensation for 
reduced insulin sensitivity. Prediabetes and type 2 diabetes represent 
different degrees of insufficiency in glucose-induced insulin response. 
As the disease progresses, β-cell mass is reduced, and eventually the β-
cells fail to secrete insulin (224). Some bariatric surgeries result in 
drastic improvements of glucose homeostasis. Improved glucose 
homeostasis can be a result of improved insulin secretion and 
sensitivity, which can be achieved by weight loss. This is also the case 
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after bariatric surgery, but the effects occur sooner than expected. 
Fasting glucose has been reported to reduce 1 week after RYGB (225, 
226) and VSG (227, 228) procedure, which was before any substantial 
weight loss could be observed. The rapid effects on glucose regulation 
support the evidence of the improvements being independently of 
weight loss produced by the procedures (229, 230). In contrast to 
RYGB and VSG, improvements in glucose homeostasis after AGB are 
entirely dependent on weight loss (231). In addition, both RYGB and 
VSG had greater increase in insulin sensitivity than that observed in 
AGB patients (232). 
1.4.3 Bariatric surgery and potential mechanisms 
Bariatric surgery is currently the most effective treatment for sustained 
weight loss and reduction of obesity-related comorbidities. The 
underlying mechanisms mediating the beneficial effects of bariatric 
surgery are not yet fully understood. Although it is generally thought 
that restriction and malabsorption are the main mechanisms mediating 
weight loss in bariatric surgery, metabolic improvement occur before 
substantial weight loss takes place, indicating that other mechanisms 
are also involved. Recent research has proposed that bariatric 
procedures achieve their physiological effects through the so-called 
BRAVE mechanisms (Bile flow alteration, Reduction of gastric size, 
Anatomical gut rearrangement and altered flow of nutrients, Vagal 
manipulation and Enteric gut hormone modulation) (233). Some of 
these mechanisms will be discussed in this section. 
Food intake and preference 
A basic principle of weight loss is reducing energy intake. A simple 
explanation to the successful weight loss following bariatric 
procedures is that the reduced stomach volume is physically limiting 
the food intake. As a matter of fact, many reports show that patients 
who undergo bariatric procedures decrease their food intake and eat 
smaller meals after surgery (234-236). However, the mechanisms 
important for the reduction in food intake appear to be more complex 
than reduced stomach size.  
Bariatric patients have reported a change of food preference, selecting 
different foods and losing interest of other foods after surgery. 
Bariatric procedures, in both rodents and humans, decreased the 
preference for high-fat intake (237-241). Together, reduced intake of 
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sweet foods (242, 243), with reduced sweet taste stimuli have also 
been reported (244). One explanation for altered food choices after 
bariatric procedures can be due to the presence of adverse symptoms 
after the consumption of certain kinds of foods, which then drives 
patients to avoid these foods. These adverse symptoms occur when the 
nutrients reach the small intestine too quickly, which causes nausea, 
abdominal pain, diarrhea, palpitations, and flushing (dumping 
syndrome) (245, 246). Several studies have also suggested that both 
bariatric patients and rodents may experience decreased food reward in 
general, but also to certain type of foods (247-249). In addition, 
bariatric patients also report decreased hunger and increased satiety 
(250-252).  
Interestingly, increased postprandial release of gut hormones 
including, GLP-1 and PYY, have been associated with bariatric 
surgery (160, 161, 253, 254). These hormones promote satiety, which 
can in part explain the increased feeling of satiety after surgery. 
Glucose homeostasis 
Besides weight loss, rapid improvement on glucose homeostasis is 
produced by some bariatric surgeries. This phenomenon has been 
hypothesized to be an effect of increased postprandial GLP-1 release 
(170, 255). In agreement, a series of studies have reported a correlation 
between the increased incretin effect and improvements in glucose 
metabolism after VSG and RYGB (256-258)  
Another interesting hypothesis stems from the observation of increased 
circulating bile acids after VSG and RYGB (259). Bile acids not only 
facilitate the absorption of fat from the intestine, they also enter the 
circulation and act on nuclear transcription factors (FXR) that regulate 
genes involved in glucose homeostasis in the liver (123, 260). Bile 
acids can also activate the receptor TGR5 present in the gut, which has 
been linked to GLP-1 secretion (195). Bariatric surgeries performed on 
mice lacking the TGR5 receptor (261) and FXR receptor (262), 
demonstrated that the beneficial effects of surgery require an intact bile 
acid signaling. Thus, the increased circulating bile acids in both VSG 
and RYGB can be important mediators of the metabolic improvements 
in these procedures (263, 264).  
Recent studies have also indicated that the gut microbiota may mediate 
some of the beneficial effects of bariatric surgery. Both short-term and 
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long-term changes to the microbiota composition have been observed 
after RYGB in humans (265-267), as well as after VSG and RYGB in 
mice (262, 268). Recent studies showed that GF mice which received 
the surgically altered microbiota gained less fat, which suggests that 
these microbial changes are capable of modulating host metabolism 
(267, 268). Interestingly, gut microbiota has also been reported to 
regulate the bile acid pool (269). Future studies will elucidate the 
interaction between bile acids and gut microbes and their role in 
bariatric surgery. 
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2 AIM 
The overall aim of my thesis was to address how the gut microbiota 
modulates the expression of INSL5 and to investigate whether it was 
regulated by bariatric surgery, and its potential involvement in 
mediating the beneficial effects of the procedure. My third aim was to 
investigate whether the microbiota contributed to the beneficial effects 
of bariatric surgery.  
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3 RESULTS 
3.1 Paper I 
3.1.1 Insl5 expression in the colon is regulated by 
microbiota and energy availability 
Insl5 in the colon was found to be one of the most significantly 
regulated genes in a micro-array based screen (270). We confirmed 
this finding by quantitative real-time polymerase chain reaction (qRT-
PCR) in two separate mouse strains. We showed that Insl5 expression 
was significantly upregulated in colon of GF Swiss Webster and 
C57Bl/6 mice compared with their CONV-R counterparts (Paper I Fig 
1A and E). We also showed that reducing the bacterial load in the mice 
with antibiotic treatment significantly increased the Insl5 expression in 
the colon (Paper I Fig 1B).  
Cells in the colon use primarily SCFAs (microbial metabolites 
produced as end-products of fermentation activities) as energy 
substrate (271). Thus, in GF mice the absence of microbiota leads to 
significantly reduced SCFAs levels (194), and as a result energy-
deprived colonocytes (113). The lack of energy in GF colonocytes has 
been previously reported to increase Gcg (the gene coding for GLP-1) 
(194). The increased Gcg expression and GLP-1 levels in the GF mice 
resulted in slower intestinal transit. We hypothesize that this is a 
physiological adaptation which allows more nutrient and energy to be 
absorbed in an energy deficit state and that the elevated Insl5 
expression in GF colon is caused by reduced energy levels.  
Indeed, we found that increasing the energy availability with energy-
rich diets or colonization in the GF mice restored the Insl5 expression 
to normal levels (Paper I Fig 1D, and F). Our data suggest that INSL5 
may play a role when energy status is low, which is in agreement with 
an earlier study reporting that plasma INSL5 is induced by fasting, and 
reduced by feeding (178).  
3.1.2 The physiological role of INSL5 
By performing immunohistochemistry, we confirmed that INSL5 is an 
L-cell hormone which is specifically expressed in the colon (178). 
Physiologic functions commonly described for L-cell hormones are 
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appetite regulation and gut transit (79, 118). To investigate whether 
INSL5 is involved in similar processes we compared wild-type and 
Insl5-/- mice, but did not obtain evidence for a role of INSL5 in 
regulation of food intake and gut transit (Paper I Fig S2D and E). 
These results contradict an earlier study by Grosse et al. reporting that 
INSL5 is a hormone that increases appetite. However, Grosse et al. 
studied the acute effect of an INSL5 injection, while we used a whole-
body Insl5 knockout mouse model. It is not uncommon to observe a 
significant effect of an exogenous peptide administration, while 
knocking out the same peptide in a mouse fails to demonstrate any 
phenotype (272). This has been previously described for ghrelin and 
GLP-1 (152, 154, 171, 172). A lack of effect in knockout mice can be 
due to redundant systems that can compensate for the loss of function 
and other adaptive responses. Another possibility is that while lacking 
an appetite hormone may not have an effect on feeding behavior, the 
increase of the same hormone might exhibit a pronounced effect (172). 
Thus, it will be interesting to investigate the role of INSL5 on appetite 
in transgenic mice with Insl5 overexpression. Interestingly, previous 
studies have reported increased food intake in GF mice (49), which we 
here report have increased Insl5 expression. However, the role of 
INSL5 in GF mice remains unclear. 
3.1.3 INSL5 and hepatic glucose production 
We found that Insl5-/- mice had impaired intraperitoneal glucose 
tolerance (Paper 1 Fig 3C), which is in agreement with a recent report 
by Burnicka-Turek et al (183). However, we did not observe any 
difference in oral glucose tolerance between the two genotypes (Paper 
I Fig 3A). A possible explanation for the different responses of the two 
glucose tolerance tests is the fact that oral but not intraperitoneal 
administered glucose activates the parasympathetic gut-brain axis 
which promotes increased glycogen storage and inhibits 
glycogenolysis (273-276). Interestingly, Insl5-/- shows lower glycogen 
levels after 6 hours fast (Paper I Fig 3J), indicating an altered 
glycogenolysis, which can contribute to the increased glucose level 
observed after an intraperitoneal glucose injection.  
Surprisingly, we next found that Insl5-/- mice have improved insulin 
tolerance (Paper I Fig 3E), which usually is not accompanied with an 
impaired glucose tolerance. The blood glucose profile after insulin 
administration, suggested that the insulin sensitivity is similar between 
Insl5-/- and WT mice, it is rather the counter-regulatory responses (i.e., 
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release of hormones such as glucagon and catecholamines) that are 
delayed or impaired in the Insl5-deficient mice. An alteration in 
counter-regulatory responses may affect the hepatic glucose production 
during conditions of low energy. Indeed, we found that Insl5-/- mice 
displayed a slightly reduced hepatic glucose production following a 
pyruvate tolerance test (Paper I Fig 3F), together with reduced liver 
G6Pase levels and activity (Paper I Fig 3G and H) after 12 fasting, 
which suggest reduced gluconeogenesis in the mice. We speculate that 
the reduced glycogen availability observed after 6 hours fast, together 
with the reduced gluconeogenesis could potentially explain the delayed 
ability to counterbalance the reduction in blood glucose during an 
insulin tolerance and further implies that INSL5 may be important to 
mediate response to energy deprived conditions (e.g., increasing 
glucose production).  
The INSL5 receptor Rxfp4 has been detected in various tissues, 
including liver (176) and myenteric neurons (178), therefore INSL5 
might act on liver directly or indirectly through a gut-brain-liver axis to 
stimulate hepatic glucose production. INSL5 might also mediate its 
effect indirectly through modulation of counter-regulatory hormones 
such as glucagon and catecholamines.  
Taken together, our data suggests that INSL5 might play a role in 
hepatic glucose production during fasting or low blood glucose 
conditions, although its effect is mild. We speculate that we might 
observe more pronounced effects of INSL5 on glucose maintenance in 
mice exposed to extreme starvation or long-term calorie restriction.  
3.2 Paper II 
3.2.1 INSL5 levels are increased following sleeve 
gastrectomy in humans 
To investigate whether INSL5 is regulated in obesity we analyzed 
serum levels in obese and lean individuals, but did not observe 
significant differences. In contrast, we found that fasting circulating 
INSL5 levels were increased 6 months following VSG. We also 
observed that INSL5 levels were reduced upon a test meal in VSG 
patients (Paper II Fig 1). Attenuated postprandial gut hormone 
responses have previously been associated with obesity (149, 167), and 
increased following bariatric surgery (160, 255, 258). INSL5 is an 
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orexigenic hormone which is increased by fasting and calorie 
restriction and declined with feeding in mice (178), and we have 
reported that Insl5 expression in colon is upregulated by reduced 
energy availability (277). Thus we speculate that the increased fasting 
INSL5 levels following VSG surgery is due to low energy status in the 
body and in particular in the colon due to reduced stomach size and 
overnight fast. Ingestion of a meal increases the energy availability in 
the body and may thus reduce the INSL5 levels. 
It is currently unknown if the increased INSL5 levels can be attributed 
to the physiological changes in the gut anatomy produced by the VSG 
per se, or indirectly by the significant weight loss caused by calorie 
restriction and a ‘fasting’ condition following VSG. In addition, the 
fact that we did not observe any difference in serum INSL5 between 
obese and lean individuals suggest that the increased INSL5 levels 
after VSG is not a result of a lower body weight per se, but rather a 
negative energy balance caused by reduced energy intake compared 
with previous eating behavior which is the case in the VSG patients 
but not the lean individuals. 
Ghrelin is an orexigenic hormone, similar to INSL5; it rises with 
prolonged fasting and decreases after a meal. Therefore, it has been 
shown to increase after weight loss via calorie restriction (278). 
Interestingly, anorexia nervosa patients demonstrated increased fasting 
ghrelin levels which decrease upon an oral glucose tolerance (279). In 
contrast, clinical studies on RYGB and VSG have reported a 
significant decrease in ghrelin levels, which might be due to reduced 
contact between the ghrelin producing cells and ingested nutrients 
(280, 281). However, beneficial effects of VSG surgery in rodents 
proved to be ghrelin independent (282).  
Future studies may reveal whether calorie restriction or anorexia 
induce INSL5 in humans. In addition, it will be interesting to study 
whether circulating INSL5 in healthy lean individuals demonstrate a 
postprandial response.  
3.2.2 Insl5 deficiency in mice does not affect VSG-
mediated beneficial effects 
To investigate whether the elevated levels of fasting INSL5 observed 
after VSG in humans contributed to beneficial outcomes of the surgery 
we performed VSG in wild-type and Insl5-deficient mice. We 
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observed that VSG produced similar reduction in body weight, body 
fat and food intake in Insl5 WT and KO mice (Paper II Fig 2A-C), as 
well as similar improvements in oral glucose tolerance (Paper II Fig 
3A,B). The relative insulin release (expressed as a percentage of basal 
insulin) increased to a similar extent in WT and KO mice (Paper II Fig 
3D). Overall, our findings indicate that in mice INSL5 is not essential 
for mediating the beneficial effects produced by VSG, but we cannot 
exclude that it may confer the beneficial effects in humans. Similarly, 
recent studies reported that bariatric surgery produced similar 
metabolic improvements between mice genetically disrupted for the 
GLP-1 receptor and WT mice (283, 284). This suggests that although 
increased GLP-1 has been reported following RYGB and VSG (255, 
258), GLP-1 activity does not appear to contribute to the improved 
metabolic features following bariatric surgery.  
To investigate whether circulating INSL5 levels also were increased in 
mice following VSG, we attempted to measure circulating INSL5 in 
serum obtained from WT mice using ELISA. However, we failed to 
achieve any conclusive results, due to nonspecific signal produced by 
the ELISA; this issue has been previously reported (178). Thus, we 
measured Insl5 expression in the colon on RNA level instead. 
Interestingly, we did not observe any gene expressional changes on 
Insl5 (data not shown) in WT-VSG compared with WT-sham mice. 
We speculate that it might be due to the fact that we harvested the 
tissues from the mice 12 weeks post-surgery, which is a time when the 
mice have already recovered from the acute weight loss produced by 
VSG initially, and instead they have reached a state where they are 
steadily gaining weight which is surpassing their starting weight pre-
surgery. 
The elevated INSL5 in humans might just be a physiological 
adaptation to the altered physiology following bariatric surgery, rather 
than contributing to the improved metabolism. However, in general, a 
dietary change post-surgery also contributes to the beneficial effects of 
bariatric surgery. Furthermore, altered food preference after bariatric 
surgery has been observed in both rodent and clinical studies (241, 
247, 285). A difference between the human cohort and our rodent 
study is that the human subjects were to choose freely what to eat post-
surgery, whereas the WT and KO mice were restricted to the high fat 
diet we provided them with. Interestingly, INSL5 has been suggested 
to be involved in food preference, where mice lacking Rxfp4 (the 
putative receptor for INSL5) demonstrated reduced preference for 
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high-fat food (178). Thus it would be interesting to speculate whether 
we would observe a different metabolic improvement of the mice 
lacking INSL5 if they were allowed to choose what type of food to eat.  
In summary, we have found that VSG induces fasting circulating 
INSL5 levels in humans following the procedure; however by 
performing VSG on Insl5-deficienet mice we conclude that INSL5 
seems not to contribute to the beneficial effects mediated by VSG. 
3.3 Paper III 
3.3.1 Sleeve gastrectomy alters the composition of 
the human gut microbiota 
Our previous observations that the microbiota is altered after RYGB 
(267) led us to test the hypothesis that the altered microbiota can 
contribute to the beneficial effects of bariatric surgery. To this end we 
had to switch to VSG as this methodology is more easily performed in 
mice and can be adapted to GF mice. First, we confirmed that VSG 
strongly affects the microbiota using a longitudinal approach. Six 
months after surgery we observed an increased abundance in lactic 
acid bacteria, Actinobacteria and Proteobacteria, together with 
decreased abundance of several clostridia species (Paper III Fig 1A). 
18 months after surgery we observed further increased abundance of 
Proteobacteria and in lactic acid bacteria, and decreased abundance of 
several Prevotella species (Paper III Fig 1B). Reduced abundance of 
clostridia has also been shown in a small cohort of VSG patients (three 
individuals followed up to 6 months after surgery) (286). In addition, 
the increased abundance of Proteobacteria and lactic acid bacteria has 
also been reported in two recent mouse studies (261, 262). We also 
observed a similar microbiota profile in our conventionally-raised 
VSG mice (Paper III Fig S1). Taken together, our findings, in 
combination with previous studies, suggest that there is a conserved 
gut microbial composition shift following VSG. The microbial profile 
after VSG consists of an enrichment of Proteobacteria and lactic acid 
bacteria and a depletion of clostridia and Prevotella. Clostridia and 
Prevotella are microbial species that are able to metabolize complex 
dietary fiber and produce SCFAs (287).  
Interestingly, the shifts in microbiota composition could be due to 
changes in dietary regimes, because reduced abundance of clostridia 
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has also been associated with a low calorie diet which consists of high 
protein/low carbohydrate intake (288, 289). Also, the decrease in 
Prevotella could be due to reduced consumption of complex dietary 
fiber (290), which is supported by the fact that VSG patients initially 
consume liquid food postoperatively. However, similar microbiota 
compositional shifts (increase in Proteobacteria and lactic acid 
bacteria, along with a decrease in clostridia) have been observed in 
individuals taking proton pump inhibitor drugs (291, 292), indicating 
that the increase in intestinal pH may serve as the main driver of 
changes in gut microbiota after VSG surgery.  
3.3.2 Surgically-altered gut microbiota may directly 
contribute to the beneficial effects of sleeve 
gastrectomy on glucose metabolism 
We showed that by transferring the VSG-altered gut microbiota from 
humans to GF recipient mice, we also transferred the improved 
glucoregulatory phenotype of VSG patients (Paper III Fig 2). These 
results indicate that the surgically-altered gut microbiota might directly 
contribute to the beneficial effects on glucose metabolism induced by 
VSG. Next, we showed that VSG surgery induced greater 
improvement on weight loss, glucose and insulin metabolism in 
CONV-R mice compared with GF mice, indicating that the gut 
microbiota is required for mediating the beneficial effects following 
VSG (Paper III Fig 3). We showed consistently reduced fasting 
glucose and HOMA index, together with increased relative insulin 
release during a glucose tolerance test in CONV-R VSG, but not GF 
VSG mice in comparison to sham-surgery control animals. In addition, 
the improvements in glucose and insulin levels in VSG mice could be 
transferred by microbiota transplantation to VSG-microbiota recipient 
mice (Paper III Fig 5). Our results indicate that the gut microbiota is 
involved in mediating the improved glucose metabolism following 
VSG.  
Bariatric surgery mediated beneficial metabolic effects have been 
shown to require the bile acids receptor TGR5 (261), as well as the bile 
acids receptor FXR (262). As the gut microbiota play an important role 
in the regulation of bile acid metabolism (269), we will continue to 
investigate whether the beneficial effects of VSG might be mediated 
by the gut microbiota´s modulation of bile acid composition and the 
actions of bile acids on their receptors. 
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4 METHODOLOGICAL CONSIDERATIONS 
Animal models are indispensable tools in biomedical research, as they 
have enabled us to understand underlying mechanisms to human 
diseases. Here, I will briefly discuss some considerations that I had in 
mind regarding the animal models that have been used in this thesis. 
For specific descriptions of the methods included in the thesis, please 
refer to the material and methods sections of Paper I, Paper II and 
Paper III. 
4.1 The utilization of two different mouse 
strains-C57Bl/6 vs. Swiss Webster 
In paper I we used two different mouse strains, C57Bl/6J and Swiss 
Webster mice. Interestingly, we observed that Insl5 expression was 80-
fold higher in GF compared with CONV-R mice on Swiss Webster 
background, whereas it only was 7-fold higher in GF compared to 
CONV-R mice on C57Bl/6J background. Thus, I thought it would be 
interesting to discuss the differences between the two mouse models.  
The C57Bl/6 is the most widely used inbred strain. More than 90% of 
all world´s publications based on mouse studies were referenced to 
C57Bl/6 (293). It is very well-characterized and the first mouse 
genome to be fully sequenced in 2005. The genome is fairly stable and 
homogenous which allows for reproducible experiments (294). 
C57BL/6 mice are commonly used for generating transgenic mouse 
models to serve as physiological and pathological models for in vivo 
experiments as well as for elucidating signaling mechanisms. C57Bl/6 
mice breed well, are long-lived, have a low susceptibility to tumors 
and have fairly low body weights (male weighs approx. 25 grams) at 
10 weeks of age. Other typical characteristics of this mouse strain 
include high susceptibility to diet-induced obesity and development of 
insulin resistance (295). Thus, C57Bl/6 is a popular model for studying 
metabolic disorders.  
The Swiss Webster mouse model is an outbred strain. In comparison to 
inbred strains, outbred strains are more genetically heterogeneous. 
Most commercial suppliers set up breeding strategies which aim to 
maintain the maximum heterozygosity in the population (296). Genetic 
traits of being an outbred strain include long life span, high disease 
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resistance, large and frequent litters, and large size (approx. 40 grams 
at 10 weeks of age). Swiss Webster mice are preferably used in 
research where the genotype is not important. For that reason it has 
been widely used as an all-purpose stock and for drug safety testing. 
Also, female Swiss Webster mice have excellent nurturing abilities, 
and thus they are often used as recipient mothers to nurture pups that 
have been delivered by caesarian section from other strains (297).  
Interestingly, we have recently observed that C57Bl/6 and Swiss 
Webster mice harbor slightly different microbiota profiles 
(Kovatcheva-Datchary, unpublished data, 2016). Moreover, the same 
strain of mice also harbors unique microbial communities in different 
animal facilities associated with different metabolic outcomes (298). 
The different microbial species present in the two models or perhaps 
other intrinsic host factors might cause distinct responses to an 
environment absent of microbes, and thus also different levels of Insl5. 
4.2 The germ-free mouse model 
The GF mouse model is widely used for studying the role of 
microbiota in mammalian physiology (52, 299). GF animals are born 
in a sterile environment, which is supplied by filtered sterile air, as 
well as sterile autoclaved food and water (300). The use of the GF 
mouse model has enabled us to answer questions regarding how a 
complete absence of microbes will affect different aspects of host 
physiology. Rederivation of transgenic mice into the GF environment 
has also allowed us to study whether actions of specific genes are 
microbiota dependent. The fast growing development of new 
sequencing platforms has enabled us to study the microbiota 
composition in various conditions. Although, many recent clinical 
studies report an altered microbiota composition in relation to different 
diseases, they have often only been association studies and have not 
established whether the microbiota is a cause or consequence of a 
disease.  However, colonization of GF mice with microbiota from 
hosts with different phenotypes or with specific bacterial strains has 
enabled us to study the causal link between the microbes and the 
disease conditions.  
To study GF mice we use their CONV-R counterparts as controls. 
CONV-R mice have a normal microbiota and are kept SPF (specific 
pathogen free), and they are fed the same autoclaved diet as the GF 
mice. There are some important physiological differences between GF 
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and CONV-R mice: GF mice are leaner, have improved glucose 
tolerance and an immature immune system compared with their 
CONV-R counterparts. In addition, the GF and CONV-R mice have 
been bred in separate colonies for several generations, which increase 
the risk of genetic drift between the two populations. Taken these 
factors into account, an observed difference in phenotype might be due 
to not only the microbiota but also other intrinsic factors. Therefore, 
while designing experiments we also include CONV-R mice treated 
with antibiotics that reduce a large amount of the microbiota to mimic 
the GF condition, to confirm our findings in the GF mice. We also 
colonize GF mice with cecum microbiota obtained from CONV-R 
mice to render conventionalized (CONV-D) control animals. 
4.3 Pros and cons of using knockout mice 
The ability to selectively delete specific target genes in mice, 
generating knockout mice, has provided a powerful tool to understand 
the underlying mechanisms to diseases. This technique can also be 
used to generate mouse models that express specific disease-associated 
proteins by replacing the normal gene with one containing a specific 
mutation. Production of knockout mice has revolutionized biomedical 
research, and it is still a powerful tool for modeling human diseases in 
mice. However, there are some potential limitations.  
Although, many genes linked to diseases in humans have a homolog in 
mice and approximately 70% of the gene-coding sequences are shared 
between humans and mice, there are many DNA sequences and 
variations that are not shared (301). This could potentially limit the 
mouse as a disease model, because a deletion of the gene may not 
produce an observable change in the mouse, or even produce different 
characteristics compared with humans with the same deletion. In 
addition, unexpected compensatory effects or activation of redundant 
mechanisms can occur when the gene of interest is missing and 
potentially mask the actual contribution of the gene in normal 
physiology. In principle, knocking out a gene, the absence of the gene 
is being studied and not the effects of the gene directly. Therefore, for 
some genes which convey their effects when they are increased, 
removal of the same genes may not necessarily produce an observable 
effect.    
Nonetheless, there are many important advantages to using knockout 
mice in research: 1) deletion of a gene is usually a very precise and 
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“clean” approach; because 2) the effects of a gene product can be 
studied without the potential side-effects and/or off-target effects of a 
pharmacological intervention; 3) there is no uncertainties regarding the 
degree of activation/ blockade of a specific gene product, in contrast to 
pharmacological treatments; and 4) deletion of a gene generates a 
chronic ablation which facilitates long-term studies without the need to 
invest in long-term pharmacological interventions.  
4.4 Bariatric surgery in mice and rodents 
Despite the large degree of similarities between humans and mice in 
anatomy, physiology and genetics, there are some differences worth 
mentioning in interpreting and extrapolating findings from rodent 
studies to the human condition after bariatric surgery. In rodent 
experiments, after surgery the animals encounter a situation that would 
never be the case for humans: they are restricted to the same high-fat 
diet that induced their obesity in the first place. Despite this, dramatic 
weight loss occurs in rodents after RYGB and VSG (240, 302). Even 
though the animals are not given the opportunity to choose different or 
healthier foods, the procedures result in significant weight loss and 
improvements of metabolic parameters. Therefore, it seems that altered 
food preference is a side effect of RYGB and VSG surgeries rather 
than the primary factor for mediating the beneficial effects.  
In contrast to humans, rodents keep growing throughout life (303), 
which together with high fat diet, results in animals regaining their 
weight after the initial weight loss a few weeks postoperatively. 
However, the animals that underwent bariatric surgery will remain a 
lower body weight compared to their sham controls, during the course 
of the study.  
An altered food choice after bariatric surgery can possibly be a 
reaction to food intolerance, which are aversive symptoms following 
the consumption of certain types of foods (245, 246). Thus, bariatric 
patients are driven to avoid those foods. Vomiting is one of the most 
common food intolerances (304). However, animal studies of food 
intolerance are few, because of the difficulties of assessing those 
symptoms in rodents, due to the fact that they cannot vomit (305). In 
addition, a reduction in sweet taste detection and a loss of cravings for 
sweets have been reported for humans (243). However, assessing these 
changes in rodents is less conclusive. Although, this has been studied 
in rodents, the procedures used (e.g., the licking rate test and two-
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bottle choice test) do not distinguish between detection and liking of 
the sweet stimuli (247, 306). 
Finally, considering the increasing number of reports that support the 
role of microbiota and bile acids in mediating the metabolic 
improvements following bariatric surgery, we need to address the fact 
that there are considerable differences in bile acid and microbiota 
profiles between humans and mice (307, 308). This may potentially 
differentiate the response to bariatric surgery between the two species. 
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5 CONCLUSION 
The conclusions from this thesis are: 
• INSL5 is regulated by the gut microbiota and energy 
availability. 
 
• INSL5 is an L-cell hormone that could play a role in promoting 
hepatic glucose production during energy deprived conditions. 
 
• Circulating fasting INSL5 is increased following VSG in 
human individuals, but INSL5 is not required for the beneficial 
effects observed after VSG in mice. 
 
• VSG alters the composition of the gut microbiota. 
 
• VSG-altered gut microbiota plays a direct role and is required 
for the improvements in glucose metabolism following VSG.   
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